Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/29/2025

Pain Management for Glaucoma Patients with Herniated Discs

First-Line Therapy

  • Tramadol is recommended as the first-line therapy for glaucoma patients with herniated discs, as it is effective against neuropathic pain and has a lower risk of respiratory depression compared to other opioids, according to the American Academy of Ophthalmology 1
  • The initial dosage of Tramadol is 50 mg 1-2 times daily, with a gradual increase up to 400 mg daily, as suggested by the American Academy of Ophthalmology 1
  • Tramadol has shown superior efficacy compared to placebo in reducing pain and improving physical function, as reported by the American Academy of Ophthalmology 1

Alternative Options

  • Gabapentin and Pregabalin are effective alternatives for neuropathic pain, with Gabapentin starting at 600 mg on the first day and increasing every 3 days up to 1800 mg, and Pregabalin starting at 75 mg at night and increasing weekly up to 600 mg daily, as recommended by the American Academy of Ophthalmology 2
  • Duloxetin and Venlafaxin have both antidepressive and central analgesic properties, with Duloxetin being effective at doses of 20-120 mg/day for neuropathic pain, as suggested by the American Academy of Ophthalmology 3

Special Considerations for Glaucoma Patients

  • NSAIDs should be avoided in glaucoma patients due to the risk of renal and gastric toxicity, as warned by the American Society of Clinical Oncology 4
  • Laxatives should be prescribed routinely for the prevention and treatment of opioid-induced constipation, as recommended by the American Society of Clinical Oncology 6

Precautions and Side Effects

  • Common side effects of Tramadol include nausea, vomiting, constipation, and sedation, as reported by the American Academy of Ophthalmology 1
  • The risk of dependence is lower compared to other opioids, but limited to second-line therapy, as noted by the American Academy of Ophthalmology 1